DeepMed Research

Orion Corporation, Orion Pharma

🇫🇮Finland

Country: 🇫🇮Finland

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Blood-Brain Barrier Penetration of Therapeutic Agents in Human

Phase 1

Completed

Conditions: CNS Disease

Interventions: Drug: ODM-104
Drug: Paracetamol

First Posted Date: 2020-10-01

Last Posted Date: 2021-04-13

Lead Sponsor: Orion Corporation, Orion Pharma

Target Recruit Count: 4

Registration Number: NCT04571996

Locations: 🇫🇮
CRST Turku, Turku, Finland

Digital Therapeutics (DTx) for Pain: Pilot Study of a Virtual Reality Software for Chronic Pain

Not Applicable

Completed

Conditions: Chronic Low Back Pain

Interventions: Other: Standard care
Other: Control software
Other: DTx for pain software

First Posted Date: 2020-01-13

Last Posted Date: 2023-11-08

Lead Sponsor: Orion Corporation, Orion Pharma

Target Recruit Count: 34

Registration Number: NCT04225884

Locations: 🇫🇮
CPU Orion Pharma, Espoo, Finland

Inspiratory Flow Parameters With Placebo Easyhaler and Placebo HandiHaler

Not Applicable

Completed

Conditions: Healthy Volunteer
COPD

Interventions: Drug: Placebo Tiotropium inhalation powder type B
Drug: Placebo Tiotropium inhalation powder type A
Drug: Placebo Spiriva capsule
Device: Substudy Placebo Spiriva® via HandiHaler
Device: Substudy Placebo Tiotropium Easyhaler

First Posted Date: 2019-11-01

Last Posted Date: 2020-01-27

Lead Sponsor: Orion Corporation, Orion Pharma

Target Recruit Count: 200

Registration Number: NCT04147572

Locations: 🇪🇪
Lung Clinic, Tartu University Hospital, Tartu, Estonia

Effects of Oral Levosimendan on Respiratory Function in Patients With Amyotrophic Lateral Sclerosis (ALS): Open-Label Extension

Phase 3

Terminated

Conditions: Amyotrophic Lateral Sclerosis

Interventions: Drug: Levosimendan

First Posted Date: 2019-05-13

Last Posted Date: 2023-03-09

Lead Sponsor: Orion Corporation, Orion Pharma

Target Recruit Count: 227

Registration Number: NCT03948178

Locations: 🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States
🇺🇸
Augusta University, Medical Centre, Augusta, Georgia, United States
🇺🇸
Neurology Associates, Lincoln, Nebraska, United States

and more 76 locations

Effect of Charcoal on Gastrointestinal Absorption of Tiotropium

Phase 1

Completed

Conditions: Healthy Volunteer Study

Interventions: Drug: Tiotropium

First Posted Date: 2019-05-10

Last Posted Date: 2019-09-23

Lead Sponsor: Orion Corporation, Orion Pharma

Target Recruit Count: 20

Registration Number: NCT03945344

Locations: 🇫🇮
Clinical Pharmacology Unit, Espoo, Finland

Safety and Pharmacokinetics of ODM-209

Phase 1

Completed

Conditions: Metastatic Breast Cancer
Castration-resistant Prostate Cancer
Prostate Cancer Metastatic
Advanced Breast Cancer

Interventions: Drug: ODM-209

First Posted Date: 2019-03-18

Last Posted Date: 2024-02-01

Lead Sponsor: Orion Corporation, Orion Pharma

Target Recruit Count: 38

Registration Number: NCT03878823

Locations: 🇫🇮
Helsinki University Central Hospital, Helsinki, Finland
🇫🇷
Institut Gustave Roussy, Villejuif, France
🇩🇰
Rigshospitalet, University Hospital of Copenhagen, Copenhagen, Denmark

and more 1 locations

Safety, Tolerability and Efficacy of DEXDOR in Pediatric Patients in ICU

Phase 4

Completed

Conditions: ICU Sedation

Interventions: Drug: Dexmedetomidine

First Posted Date: 2019-01-23

Last Posted Date: 2019-01-23

Lead Sponsor: Orion Corporation, Orion Pharma

Target Recruit Count: 60

Registration Number: NCT03813277

Locations: 🇷🇺
State Federal-Funded Educational Institution of, Moscow, Russian Federation

Efficacy and Safety of Remo-Wax for Removal of Impacted Earwax

Not Applicable

Completed

Conditions: Cerumen Impaction of Both Ears

Interventions: Device: Remo-Wax

First Posted Date: 2019-01-14

Last Posted Date: 2019-05-15

Lead Sponsor: Orion Corporation, Orion Pharma

Target Recruit Count: 52

Registration Number: NCT03802903

Locations: 🇱🇹
LOR Clinic, Vilnius, Lithuania

Salmeterol/Fluticasone Easyhaler in the Treatment of Asthma and COPD

Completed

Conditions: Chronic Obstructive Pulmonary Disease
Asthma

First Posted Date: 2018-11-28

Last Posted Date: 2020-02-28

Lead Sponsor: Orion Corporation, Orion Pharma

Target Recruit Count: 231

Registration Number: NCT03755544

Locations: 🇩🇪
Lungenpraxis, Hamburg, Germany

Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS

Phase 3

Completed

Conditions: Amyotrophic Lateral Sclerosis

Interventions: Drug: Placebo for levosimendan
Drug: Levosimendan

First Posted Date: 2018-04-20

Last Posted Date: 2022-05-11

Lead Sponsor: Orion Corporation, Orion Pharma

Target Recruit Count: 496

Registration Number: NCT03505021

Locations: 🇨🇦
Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
🇨🇦
Moncton Hospital, Southeast Regional Health Authority, Moncton, New Brunswick, Canada
🇺🇸
Hospital for Special Care, New Britain, Connecticut, United States

and more 101 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy